Financial Performance - The company achieved a net profit attributable to shareholders of RMB 111,336,627.48 for the first half of 2024, representing a 6.12% increase compared to RMB 104,917,854.04 in the same period last year[4]. - Total revenue for the first half of 2024 was RMB 824,918,018.49, a decrease of 7.30% from RMB 889,901,502.72 in the previous year[19]. - The net profit attributable to shareholders was 111 million RMB, an increase of 6.12% year-on-year[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 101 million RMB, up 5.90% from the previous year[38]. - Basic earnings per share for the current period is CNY 0.64, a 6.67% increase compared to CNY 0.60 in the same period last year[20]. - Diluted earnings per share decreased by 3.33% to CNY 0.58 from CNY 0.60 year-over-year[20]. - The total comprehensive income attributable to the parent company was CNY 92,463,894.56, compared to CNY 104,989,090.60 in the previous year, reflecting a decrease of 11.9%[111]. - The company reported a total comprehensive income of 66,908,306.85 RMB for the current period, reflecting a significant financial performance[129]. Cash Flow and Liquidity - The net cash flow from operating activities was negative RMB 43,184,531.68, a significant decline of 126.32% compared to a positive cash flow of RMB 164,083,652.44 in the same period last year[19]. - The company’s operating cash flow net amount decreased by 126.32% to -43.18 million RMB due to reduced revenue and increased payment cycles for raw materials[45]. - Cash inflows from operating activities totaled CNY 883,173,343.03, down from CNY 974,956,396.15 in the first half of 2023, indicating a decline of 9.4%[114]. - The net cash flow from operating activities for the first half of 2024 was -28,680,436.82 RMB, an improvement from -117,491,668.47 RMB in the same period of 2023[116]. - The ending cash and cash equivalents balance decreased to 326,064,981.97 RMB from 747,665,583.23 RMB in the previous year, representing a decline of approximately 56%[116]. - The company’s cash and cash equivalents decreased by 57.58% to ¥587,007,518.31, accounting for 17.58% of total assets[46]. Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 3,338,173,352.09, down 1.38% from RMB 3,384,898,669.64 at the end of the previous year[19]. - The company's total liabilities were CNY 1.38 billion, a slight decrease from CNY 1.41 billion at the end of 2023[104]. - The company's equity attributable to shareholders was CNY 1.95 billion, down from CNY 1.97 billion at the end of 2023[104]. - The company's current assets totaled CNY 1.94 billion, a decrease from CNY 2.23 billion as of December 31, 2023[102]. - The company's total assets decreased to CNY 3,057,511,398.28 from CNY 3,147,476,703.63, reflecting a decline of 2.8%[107]. - The company's total liabilities decreased to CNY 1,436,467,331.82, down from CNY 1,483,373,579.25, a reduction of 3.2%[107]. Investments and Capital Structure - The company plans to increase its share capital by 30% through a capital reserve transfer, raising the total share capital to 179,377,241 shares[20]. - The company has made equity investments totaling ¥33,000 million in Zhejiang Rongtai Health Electric Co., Ltd., holding a 100% stake[50]. - The company has invested ¥16,099.46 million in Shanghai Airongda Fitness Technology Co., Ltd., also holding a 100% stake[50]. - The company has committed a total investment of RMB 59,398.23 million in the Huzhou Nanxun Rongtai Massage Chair Manufacturing Base project, with an actual investment of RMB 2,167.31 million in the current year, representing a progress of 15.35%[54]. - The company raised a total of CNY 600 million through convertible bonds, with a net amount of CNY 593,982,329.04 after deducting issuance costs[80]. - The total number of shares increased from 138,974,371 to 179,377,241 after issuing new shares[85]. Research and Development - The company completed 15 R&D projects and obtained 10 invention patents, 10 utility model patents, and 14 design patents during the reporting period[41]. - The company’s R&D expenses increased by 2.29% to 38.12 million RMB, mainly due to higher salaries for R&D personnel[44]. - Research and development expenses increased slightly to CNY 38,122,653.47, compared to CNY 37,267,618.96 in the previous year[110]. Market and Industry - The company operates in the massage equipment industry, which is closely tied to global economic conditions and consumer health awareness[24]. - The main business includes the design, research and development, production, and sales of massage equipment, aiming to provide a healthy lifestyle for users[25]. - The company is actively expanding its market presence and has signed a land purchase agreement in Thailand to enhance its production capabilities[42]. - The company’s international orders have shown mixed performance, with significant recovery in the European and Middle Eastern markets, while the Korean market experienced a notable decline in the first quarter[39]. Shareholder and Governance - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares (including tax) based on the total share capital on the dividend distribution date[4]. - The company has approved a plan for the 2024 employee stock ownership plan, details of which are available on the Shanghai Stock Exchange website[71]. - The total number of ordinary shareholders reached 11,752 by the end of the reporting period[89]. - The largest shareholder, Lin Qi, holds 45,370,299 shares, accounting for 25.29% of the total shares[89]. - The company has not reported any changes in the voting rights of shareholders or any related party transactions among the top shareholders[91]. Risks and Challenges - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is comprised of raw materials, which could impact net profit growth if prices rise significantly[63]. - The competitive landscape in the massage equipment market is intensifying, prompting the company to increase R&D investment and focus on brand promotion to maintain market share[67]. - The company is exposed to foreign exchange risks due to its export business primarily being settled in USD, and it plans to manage this risk through various strategies[66]. Legal and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period[75]. - The company has not received any penalties or corrective actions related to legal violations during the reporting period[75]. - The company has committed to avoid competition with its controlling shareholders until October 2026[73]. Accounting and Financial Reporting - The company’s financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[140]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[147]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets, liabilities, income, and expenses accordingly[152]. - The company recognizes financial assets and liabilities at fair value on the transaction date when it becomes a party to a financial instrument contract[156].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603579 证券简称：荣泰健康 公告编号：2024-058 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 关于2024年半年度募集资金存放与实际使用情况的专 项报告 | | | 1 | 年 2023 31 | 12 | 月 | 日募集资金专户余额 | 32,039.07 | | --- | --- | --- | --- | --- | | 减：募集资金投资项目本期投入资金 | | | | 2,167.31 | | 减：暂时闲置募集资金购买大额存单 | | | | 43,000.00 | | 加：赎回大额存单 | | | | 30,000.00 | | 加：2024 年 | | 1-6 | 月扣除手续费后存款利息收入 | 270.68 | | 加：2024 年 | | 1-6 | 月理财产品投资收益 | 262.66 | | 2024 年 月 | 6 | 30 | 日募集资金专户余 ...

上海荣泰健康科技股份有限公司 对外担保管理制度 第一章 总 则 第一条 为了规范上海荣泰健康科技股份有限公司（以下简称"公司"）的对 外担保行为，根据《中华人民共和国民法典》（以下简称《民法典》）、《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证 券法》）、《上海证券交易所股票上市规则》等法律法规、规范性文件，以及《上海 荣泰健康科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合 公司的实际情况，特制定本制度。 第二条 本制度适用于本公司及本公司的全资子公司、控股子公司（以下共同 简称"子公司"）。 第九条 公司可以为具有独立法人资格和较强偿债能力并具有以下条件之一 的单位提供担保： （一）因公司业务需要的互保单位； （二）与公司具有重要业务关系的单位； 第四条 子公司的对外担保，视同公司行为，其对外担保应执行本制度，并应 获得公司董事会批准。公司子公司在其董事会或股东会做出决议后应及时通知公 司董事会秘书。 第五条 公司对外担保实行统一管理，非经公司董事会或股东大会批准，任何 人无权以公司名义签署对外担保的合同、协议或其他类似的法律文件。 第六条 公司 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-060 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于变更公司 2021 年回购股份用途暨注销部分回购 股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 4、回购资金来源：公司自有资金。 一、变更前回购方案概述 公司于2021年2月4日召开第三届董事会第十次会议及第三届监事会第十次 变更前回购股份用途：用于股权激励及员工持股计划。 变更后回购股份用途：用于注销并减少公司注册资本。 上海荣泰健康科技股份有限公司（以下简称"公司"）拟注销回购专用 证券账户中 2021 年回购股份方案已回购的 1,995,479 股股份，注销完成 后公司总股本将由 179,377,241 股变更为 177,381,762 股，注册资本将 由 179,377,241 元变更为 177,381,762 元。本次变更回购股份用途及注 销事项尚需提交公司股东大会审议 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-062 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于注销部分回购股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 上海荣泰健康科技股份有限公司（以下简称"公司"）于2024年8月27日召 开第四届董事会第十七次会议及第四届监事会第十三次会议，审议通过了《关于 变更公司2021年回购股份用途暨注销部分回购股份的议案》以及《关于变更注册 资本及修订<公司章程>的议案》。以上议案还需经过股东大会审议。具体回购注 销情况如下： （一）本次注销回购股票的相关规定及注销股份数量 公司于 2021 年 2 月 4 日召开第三届董事会第十次会议及第三届监事会第十 次会议，逐项审议通过了《关于回购公司股份预案的议案》。回购股份规模：不 低于人民币 5,000 万元（含 5,000 万元），不超过人民币 10,000 万元（含 10,00 ...

关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 证券代码：603579 证券简称：荣泰健康 公告编号：2024-063 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2024 年第二次临时股东大会 召开的日期时间：2024 年 9 月 13 日 14 点 00 分 召开地点：上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号楼荣泰大厦 公司会议室 股东大会召开日期：2024年9月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 13 日 至 2024 年 9 月 ...

上海荣泰健康科技股份有限公司董事会议事规则 第一章 总则 第一条 为明确上海荣泰健康科技股份有限公司（以下简称"公司"）董事 会的职责权限，规范董事会组织、董事行为及操作规则，充分发挥董事会的作用， 督促董事正确履行其权利和义务,完善公司的法人治理结构，根据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上市公司治理准则》、《上海证 券交易所股票上市规则》等法律法规、规范性文件，以及《上海荣泰健康科技股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，特制定本规则, 作为董事及董事会运作的行为准则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会，董事会受股东大会的委托，负责经营和管理 公司的法人财产。董事会对股东大会负责，在《公司章程》和股东大会赋予的职 权范围内行使职权。 第三条 公司董事会由 9 名董事组成，其中独立董事 3 名，设董事长 1 名。 公司董事会中兼任公司高级管理人员以及由职工代表担任的董事人数总计 不得超过公司董事总数的 1/2。 第四条 董事会下设董事会办公室，负责处理董事会日常事务，其具体职责 另行规定。 第五条 公司董事会设立战略、审计、提名、薪酬与考核等专 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2024-061 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于变更公司注册资本及修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、审议程序情况 2024 年 8 月 27 日，上海荣泰健康科技股份有限公司（以下简称"公司"） 召开了第四届董事会第十七次会议、第四届监事会第十三次会议，审议通过《关 于变更注册资本及修订<公司章程>的议案》，同时提请公司股东大会授权经理层 办理公司工商登记变更、备案等事宜。该议案尚需提请公司 2024 年第二次临时 股东大会予以审议。 二、变更公司注册资本的情况 公司注册资本由 138,973,899 元变更为 177,381,762 元，公司股份总数由 138,973,899 股变更为 177,381,762 股。 （一） 公司 2023 年年度利润分配方案资本公积金转增股本 公司 2023 年年度利润分配方案，以资本公积金向全体股东每 ...